Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trump Rollback Of ACA Birth-Control Coverage Mandate To Push Down Gains In IUD Sales

Executive Summary

More religious-based college employers, and for-profit businesses with moral objections to contraceptive coverage, will be able to issue health plans denying intrauterine device and birth control coverage to their employees and students starting in 2018, under the administration's Oct. 6-issued "conscience rights" exemptions from Affordable Care Act (ACA) requirements. The interim final rules could dampen sales of IUDs and implants that have risen 5% in the last year at Bayer Healthcare and Allergan.

You may also be interested in...



How Kavanaugh High Court Pick Could Increase IUD Sales

A look at what impacts a changed court could have on abortion rights, and related IUD products that device companies Bayer and Allergan make and sell, plus a peek at new contraceptive products on the horizon.

HHS Plan To Exempt Employers From Birth-Control Mandate Threatens IUD Sales

An HHS draft proposal to broaden the "religious and moral objections" exemption from an Affordable Care Act rule mandating that employers cover employees' contraceptive use in health care plans, threatens US sales of intrauterine devices (IUDs), which total more than $1bn annually.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

Topics

Related Companies

UsernamePublicRestriction

Register

MT121607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel